Sierra Ocean LLC Takes Position in Johnson & Johnson (NYSE:JNJ)

Sierra Ocean LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,042 shares of the company's stock, valued at approximately $295,000.

A number of other large investors also recently bought and sold shares of JNJ. IFS Advisors LLC grew its holdings in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter worth $31,000. RPg Family Wealth Advisory LLC purchased a new position in Johnson & Johnson during the 3rd quarter worth $35,000. Bay Harbor Wealth Management LLC acquired a new position in Johnson & Johnson during the 4th quarter valued at about $32,000. Finally, Mowery & Schoenfeld Wealth Management LLC raised its stake in Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after buying an additional 91 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded up $3.71 during trading on Friday, hitting $163.39. 6,875,582 shares of the stock traded hands, compared to its average volume of 8,893,225. The company has a fifty day moving average price of $148.61 and a two-hundred day moving average price of $155.89. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a market cap of $393.37 billion, a price-to-earnings ratio of 24.54, a P/E/G ratio of 2.53 and a beta of 0.52. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the firm posted $2.29 earnings per share. The company's revenue was up 5.3% compared to the same quarter last year. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.04%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson's payout ratio is currently 74.59%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research analyst reports. Guggenheim boosted their price target on Johnson & Johnson from $162.00 to $166.00 and gave the stock a "neutral" rating in a research note on Monday, February 3rd. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 23rd. Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an "outperform" rating and a $190.00 price objective on the stock. Barclays lifted their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a research report on Tuesday, January 28th. Finally, StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $170.67.

Insider Activity

In related news, Director Mark A. Weinberger purchased 1,000 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.